Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to $69.3 million.

  • Ligand Pharmaceuticals' Net Cash Flow rose 5362.61% to $69.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.4 million, marking a year-over-year increase of 7138.81%. This contributed to the annual value of $50.5 million for FY2024, which is 32911.3% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Net Cash Flow of $69.3 million as of Q3 2025, which was up 5362.61% from $20.1 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Net Cash Flow ranged from a high of $69.3 million in Q3 2025 and a low of -$60.3 million during Q2 2023
  • Its 5-year average for Net Cash Flow is $4.7 million, with a median of -$1.2 million in 2022.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Net Cash Flow surged by 114658.31% in 2022, and later crashed by 63771.48% in 2023.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Net Cash Flow stood at -$3.9 million in 2021, then surged by 1146.58% to $40.9 million in 2022, then tumbled by 92.43% to $3.1 million in 2023, then surged by 230.62% to $10.2 million in 2024, then surged by 576.92% to $69.3 million in 2025.
  • Its Net Cash Flow stands at $69.3 million for Q3 2025, versus $20.1 million for Q2 2025 and -$25.3 million for Q1 2025.